Corneal lymphangiogenesis in herpetic stromal keratitis

Survey of Ophthalmology

Volumn 60, Issue 1, 2015, Pages 60-71

  Park, Paul J ^a   Chang, Michael ^a   Garg, Nitin ^a   Zhu, Jimmy ^a   Chang, Jin Hong ^a   Shukla, Deepak ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Cornea; Herpes simplex virus 1; Lymphangiogenesis; Neovascularization; Vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; AGANIRSEN; ANTIVIRUS AGENT; BEVACIZUMAB; CORTICOSTEROID; CXCL1 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INSULIN RECEPTOR SUBSTRATE 1; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2;

CATARACT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA STROMA; CORNEA TRANSPLANTATION; DRUG PENETRATION; EYE DISEASE; GLAUCOMA; GRAFT REJECTION; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPETIC STROMAL KERATITIS; HUMAN; INNATE IMMUNITY; KERATITIS; LYMPHANGIOGENESIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; REVIEW; VIRUS ENTRY; VIRUS PATHOGENESIS; ANIMAL; CORNEA; DISEASE MODEL; KERATITIS, HERPETIC; LYMPH VESSEL; PATHOPHYSIOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; CORNEA; CORNEAL STROMA; DISEASE MODELS, ANIMAL; HUMANS; KERATITIS, HERPETIC; LYMPHANGIOGENESIS; LYMPHATIC VESSELS;

EID: 84918825271     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2014.06.001     Document Type: Review

References (156)

1. Albuquerque R.J., Hayashi T., Cho W.G., et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009, 15:1023-1030.
2. Ambati B.K., Nozaki M., Singh N., et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443:993-997.
3. Arduino P.G., Porter S.R. Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features. JOral Pathol Med 2008, 37:107-121.
4. Azar D.T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis. Trans Am Ophthalmol Soc 2006, 104:264-302.
5. Bachmann B.O., Luetjen-Drecoll E., Bock F., et al. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularization. Br J Ophthalmol 2009, 93:1075-1080.
6. Baluk P., Tammela T., Ator E., et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. JClin Invest 2005, 115:247-257.
7. Banerjee K., Biswas P.S., Kim B., et al. CXCR2-/- Mice Show Enhanced Susceptibility to Herpetic Stromal Keratitis: A Role for IL-6-Induced Neovascularization. JImmunol 2004, 172:1237-1245.
8. Banerjee K., Biswas P.S., Kumaraguru U., et al. Protective and pathological roles of virus-specific and bystander CD8+ T cells in herpetic stromal keratitis. JImmunol 2004, 173:7575-7583.
9. Banerji S., Ni J., Wang S.X., et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. JCell Biol 1999, 144:789-801.
10. Barker N.H. Ocular herpes simplex. Clin Evid 2006, 917-923.
11. Bauer D., Mrzyk S., Van Rooijen N., et al. Macrophage-depletion influences the course of murine HSV-1 keratitis. Curr Eye Res 2000, 20:45-53.
12. Biswas P.S., Banerjee K., Kim B., Rouse B.T. Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis: possible role for IL-1 in herpetic stromal keratitis pathogenesis. JImmunol 2004, 172:3736-3744.
13. Biswas P.S., Banerjee K., Kinchington P.R., et al. Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Exp Eye Res 2006, 82:46-54.
14. Biswas P.S., Banerjee K., Zheng M., et al. Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. JLeukoc Biol 2004, 76:868-875.
15. Biswas P.S., Rouse B.T. Early events in HSV keratitis-setting the stage for a blinding disease. Microbes Infect 2005, 7:799-810.
16. Bock F., Onderka J., Dietrich T., et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007, 48:2545-2552.
17. Bouley D.M., Kanangat S., Rouse B.T. The role of the innate immune system in the reconstituted SCID mouse model of herpetic stromal keratitis. Clin Immunol Immunopathol 1996, 80:23-30.
18. Breiteneder-Geleff S., Soleiman A., Kowalski H., et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999, 154:385-394.
19. Bryant-Hudson K.M., Chucair-Elliott A.J., Conrady C.D., et al. HSV-1 targets lymphatic vessels in the eye and draining lymph node of mice leading to edema in the absence of a functional type I interferon response. Am J Pathol 2013, 183:1233-1242.
20. Carnahan M.C., Goldstein D.A. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000, 11:478-483.
21. Carr D.J., Chodosh J., Ash J., et al. Effect of anti-CXCL10 monoclonal antibody on herpes simplex virus type 1 keratitis and retinal infection. JVirol 2003, 77:10037-10046.
22. Carr D.J., Härle P., Gebhardt B.M. The immune response to ocular herpes simplex virus type 1 infection. Exp Biol Med 2001, 226:353-366.
23. Chang J.H., Gabison E.E., Kato T., et al. Corneal neovascularization. Curr Opin Ophthalmol 2001, 12:242-249.
24. Chang J.H., Garg N.K., Lunde E., et al. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol 2012, 57:415-429.
25. Chen L., Hamrah P., Cursiefen C., et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004, 10:813-815.
26. Collum L.M., Grant D.M. Adouble-blind comparative trial of acyclovir and adenine arabinoside in combination with dilute betamethasone in the management of herpetic disciform keratitis. Curr Eye Res 1987, 6:221-224.
27. Collum L.M., Logan P., Ravenscroft T. Acyclovir (Zovirax) in herpetic disciform keratitis. Br J Ophthalmol 1983, 67:115-118.
28. Conrady C.D., Zheng M., Stone D.U., et al. CD8+ T cells suppress viral replication in the cornea but contribute to VEGF-C-induced lymphatic vessel genesis. JImmunol 2012, 189:425-432.
29. Cueni L.N., Detmar M. The lymphatic system in health and disease. Lymphat Res Biol 2008, 6:109-122.
30. Cursiefen C. Immune privelege and angiogenic privelege of the cornea. Chem Immunol Allergy 2007, 92:50-57.
31. Cursiefen C., Cao J., Chen L., et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004, 45:2666-2673.
32. Cursiefen C., Chen L., Borge L.P., et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. JClin Invest 2004, 113:1040-1050.
33. Cursiefen C., Chen L., Dana M.R., et al. Corneal lymphangiogenesis: evidence, mechansims, and implications for corneal transplant immunology. Cornea 2003, 22:273-281.
34. Cursiefen C., Chen L., Saint-Geniez M., et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006, 103:11405-11410.
35. Daheshia M., Kanangat S., Rouse B.T. Production of key molecules by ocular neutrophils early after herpetic infection of the cornea. Exp Eye Res 1998, 67:619-624.
36. Darougar S., Wishart M.S., Viswalingam N.D. Epidemiological and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol 1985, 69:2-6.
37. Dastjerdi M.H., Sadrai Z., Saban D.R., et al. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011, 52:8718-8723.
38. Dietrich T., Bock F., Yuen D., et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. JImmunol 2010, 184:535-539.
39. Divito S.J., Hendricks R.L. Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis. Invest Ophthalmol Vis Sci 2008, 49:1488-1495.
40. Duan R., Remeijer L., van Dun J.M., et al. Granulocyte macrophage colony-stimulating factor expression in human herpetic stromal keratitis: implications for the role of neutrophils in HSK. Invest Ophthalmol Vis Sci 2007, 48:277-284.
41. Eisenberg R.J., Atanasiu D., Cairns T.M., et al. Herpes virus fusion and entry: a story with many characters. Viruses 2012, 4:800-832.
42. Ellenberg D., Azar D.T., Hallak J.A., et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res 2010, 29:208-248.
43. Epstein R.J., Seedor J.A., Dreizen N.G., et al. Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. Ophthalmology 1987, 94:935-944.
44. Farooq A.V., Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol 2012, 57:448-462.
45. Frank G.M., Divito S.J., Maker D.M., et al. Anovel p40-independent function of IL-12p35 is required for progression and maintenance of herpes stromal keratitis. Invest Ophthalmol Vis Sci 2010, 51:3591-3598.
46. Galea I.B., Bechmann I., Perry V.H. What is immune privilege (not)?. Trends Immunol 2007, 28:12-18.
47. Gangappa S., Deshpande S., Rouse B.T. Bystander activation of CD4+ T cells accounts for herpetic ocular lesions. Invest Ophthalmol Vis Sci 2000, 41:453-459.
48. Gaudio P.A. Areview of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm 2004, 12:169-192.
49. Gausas R.E., Gonnering R.S., Lemke B.N., et al. Identification of human orbital lymphatics. Ophthal Plast Reconstr Surg 1999, 15:252-259.
50. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008, 27:1195-1199.
51. Gimenez F., Suryawanshi A., Rouse B.T. Pathogenesis of herpes stromal keratitis-a focus on corneal neovascularization. Prog Retin Eye Res 2012, 33:1-9.
52. Hajrasouliha A.R., Funaki T., Sadrai Z., et al. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest Ophthalmol Vis Sci 2012, 53:1244-1250.
53. Hamrah P., Huq S.O., Liu Y., et al. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. JLeukoc Biol 2003, 74:172-178.
54. Hamrah P., Liu Y., Zhang Q., et al. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest Ophthalmol Vis Sci 2003, 44:581-589.
55. Hayashi K., Hooper L.C., Detrick B., et al. HSV immune complex (HSV-IgG: IC) and HSV-DNA elicit the production of angiogenic factor VEGF and MMP-9. Arch Virol 2009, 154:219-226.
56. Hazlett L.D., Hendricks R.L. Reviews for immune privilege in the year 2010: immune privelege and infection. Ocul Immunol Inflamm 2010, 18:237-243.
57. He J., Ichimura H., Iida T., et al. Kinetics of cytokine production in the cornea and trigeminal ganglion of C57BL/6 mice after corneal HSV-1 infection. JInterferon Cytokine Res 1999, 19:609-615.
58. Herold B.C., WuDunn D., Soltys N., et al. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. JVirol 1991, 65:1090-1098.
59. Holland E.J., Schwartz G.S. Classification of herpes simplex virus keratitis. Cornea 1999, 18:144-154.
60. Hong Y.K., Shin J.W., Detmar M. Development of the lymphatic vascular system: a mystery unravels. Dev Dyn 2004, 231:462-473.
61. Hori J., Niederkorn J.Y. Immunogenecity and immune privelege of corneal allografts. Chem Immunol Allergy 2007, 92:290-299.
62. Hos D., Regenfuss B., Bock F., et al. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis. Invest Ophthalmol Vis Sci 2011, 52:5778-5785.
63. Ishitani A., Geraghty D.E. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 1992, 89:3947-3951.
64. Jager M.J., Bradley S., Atherton S., et al. Presence of Langerhans cells in the central cornea linked to the development of ocular herpes in mice. Exp Eye Res 1992, 54:835-841.
65. Kajiya K., Hirakawa S., Detmar M. Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol 2006, 169:1496-1503.
66. Kaplan H.J., Streilein J.W. Immune response to immunization via the anterior chamber of the eye. I.F. lymphocyte-induced immune deviation. JImmunol 1977, 118:809-814.
67. Kataru R.P., Jung K., Jang C., et al. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood 2009, 113:5650-5659.
68. Kaye S., Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res 2006, 25:355-380.
69. Keadle T.L., Stuart P.M. Interleukin-10 (IL-10) ameliorates corneal disease in a mouse model of recurrent herpetic keratitis. Microb Pathog 2005, 38:13-21.
70. Keadle T.L., Usui N., Laycock K.A., et al. IL-1 and TNF-alpha are important factors in the pathogenesis of murine recurrent herpetic stromal keratitis. Invest Ophthalmol Vis Sci 2000, 41:96-102.
71. Kim B., Lee S., Suvas S., et al. Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects. JImmunol 2005, 175:509-516.
72. Kim B., Tang Q., Biswas P.S., et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes. Am J Pathol 2004, 165:2177-2185.
73. Knickelbein J.E., Hendricks R.L., Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: anevidenced-based review. Surv Ophthalmol 2009, 54:226-234.
74. Kojima T., Azar D.T., Chang J.H. Neostatin-7 regulates bFGF-induced corneal lymphangiogenesis. FEBS Lett 2008, 582:2515-2520.
75. Kovats S., Main E.K., Librach C., et al. Aclass I antigen, HLA-G, expressed in human trophoblasts. Science 1990, 248:220-223.
76. Krug A., Luker G.D., Barchet W., et al. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004, 103:1433-1437.
77. Krummenacher C., Baribaud F., Ponce de Leon M., et al. Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology 2004, 322:286-299.
78. Kurt-Jones E.A., Chan M., Zhou S., et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contribute to lethal encephalitis. Proc Natl Acad Sci USA 2004, 101:1315-1320.
79. Kwong A.D., Frenkel N. The herpes simplex virus virion host shutoff function. JVirol 1989, 63:4834-4839.
80. Lambe T., Leung J.C., Ferry H., et al. Limited peripheral T cell anergy predisposes to retinal autoimmunity. JImmunol 2007, 178:4276-4283.
81. Larkin D.F. Corneal transplantation for herpes simplex keratitis. Br J Ophthalmol 1998, 82:107-108.
82. Le Discorde M., Moreau P., Sabatier P., et al. Expression of HLA-G in human cornea, an immune-priveleged tissue. Hum Immunol 2003, 64:1039-1044.
83. Lee N., Llano M., Carretero M., et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998, 95:5199-5204.
84. Lee S., Zheng M., Deshpande S., et al. IL-12 suppresses the expression of ocular imunoinflammatory lesions by effects on angiogenesis. JLeukoc Biol 2002, 71:469-476.
85. Lee S., Zheng M., Kim B., et al. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. JClin Invest 2002, 110:1105-1111.
86. Li H., Zhang J., Kumar A., et al. Herpes simplex virus 1 infection induces the expression of proinflammatory cytokines, interferons and TLR7 in human corneal epithelial cells. Immunology 2006, 117:167-176.
87. Liesegang T.J. Classification of herpes simplex virus keratitis and anterior uveitis. Cornea 1999, 18:127-143.
88. Liesegang T.J. Herpes simplex virus epidemiology and ocular importance. Cornea 2001, 20:1-13.
89. Liesegang T.J., Melton L.J., Daly P.J., Ilstrup D.M. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989, 107:1155-1159.
90. Lim L., Pesudovs K., Coster D.J. Penetrating keratoplasty for keratoconus: visual outcome and success. Ophthalmology 2000, 107:1125-1131.
91. Lohela M., Saaristo A., Veikkola T., et al. Lymphangiogenic growth factors, receptors and therpies. Thromb Haemost 2003, 90:167-184.
92. Lundberg P., Welander P., Han X., et al. Herpes simplex virus type 1 DNA is immunostimulatory invitro and invivo. JVirol 2003, 77:11158-11169.
93. Maruyama K., Ii M., Cursiefen C., et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. JClin Invest 2005, 115:2363-2372.
94. McGhee C.N., Dean S., Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002, 25:33-55.
95. Medawar P.B. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948, 29:58-69.
96. Mercadal C.M., Bouley D.M., DeStephano D., et al. Herpetic stromal keratitis in the reconstituted scid mouse model. JVirol 1993, 67:3404-3408.
97. Miller J.K., Laycock K.A., Nash M.M., et al. Corneal Langerhans cell dynamics after herpes siplex virus reactivation. Invest Ophthalmol Vis Sci 1993, 34:2282-2290.
98. Minagawa H., Hashimotor K., Yanagi Y. Absence of tumour necrosis factor facilitates primary and recurrent herpes simplex virus-1 infections. JGen Virol 2004, 85:343-347.
99. Mulik S.S., Sharma S., Suryawanshi A., et al. Activation of Endothelial Roundabout Receptor 4 Reduces the Severity of Virus-Induced Keratitis. JImmunol 2011, 186:7195-7204.
100. Nagy J.A., Vasile E., Feng D., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. JExp Med 2002, 196:1497-1506.
101. Nakao S., Hafezi-Moghadam A., Ishibashi T. Lymphatics and lymphangiogenesis in the eye. JOphthalmol 2012, 2012:783163.
102. Nakao S., Noda K., Zandi S., et al. VAP-1 mediated M2 macrophage infiltration underlies IL-1β- but not VEGF-A-induced lymph- and angiogenesis. Am J Pathol 2011, 178:1913-1921.
103. Newell C.K., Martin S., Sendele D., et al. Herpes simplex virus-induced stromal keratitis: role of T lymphocyte subsets in immunopathology. JVirol 1989, 63:769-775.
104. Niederkorn J.Y. The immune privelege of corneal grafts. JLeukoc Biol 2003, 74:167-171.
105. Niederkorn J.Y. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006, 7:354-359.
106. Niederkorn J.Y., Chiang E.Y., Ungchusri T., et al. Expression of a nonclassical MHC class Ib molecule in the eye. Transplantation 1999, 68:1790-1799.
107. Numasaki M., Fukushi J., Ono M., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627.
108. Oakes J.E., Monteiro C.A., Cubitt C.L., et al. Induction of interleukin-8 gene expression is associated with herpes simplex virus infection of human corneal keratocytes but not human corneal epithelial cells. JVirol 1993, 67:4777-4784.
109. Oliver G. Lymphatic vasculature development. Nat Rev Immunol 2004, 4:35-45.
110. Olsson A.K., Dimberg A., Kreuger J., et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
111. Paavonen K., Mandelin J., Partanen T., et al. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. JRheumatol 2002, 29:39-45.
112. Pepose JD: Herpes simplex virus diseases: anterior segment of the eye, in Pepose JS, Holand GN, Wilhelmus KR (eds): Ocular Infection and Immunity. St. Louis, MO, Mosby Year Book; 1996, pp.905-936.
113. Podgrabinska S., Braun P., Velasco P., et al. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci USA 2002, 99:16069-16074.
114. Power W.J., Hillery M.P., Benedict-Smith A., et al. Acyclovir ointment plus topical betamethasone or placebo in first episode disciform keratitis. Br J Ophthalmol 1992, 76:711-713.
115. Regenfuss B., Bock F., Cursiefen C. Corneal angiogenesis and lymphangiogenesis. Curr Opin Allergy Clin Immunol 2012, 12:548-554.
116. Regenfuss B., Bock F., Parthasarathy A., et al. Corneal (lymph)angiogenesis-from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 2008, 6:191-201.
117. Remeijer L., Maertzdorf J., Doornenbal P., et al. Herpes simplex virus 1 transmission through corneal transplantation. Lancet 2001, 357:442.
118. Rouas-Freiss N., Gonçalves R.M., Menier C., et al. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997, 94:11520-11525.
119. Rouas-Freiss N., Khalil-Daher I., Marchal-Bras Goncalves R., et al. Role of HLA-G in maternal-fetal immune tolerance. Transplant Proc 1999, 31:724-725.
120. Rowe A.M., St Leger A.J., Jeon S., et al. Herpes keratitis. Prog Retin Eye Res 2013, 32:88-101.
121. Russell R.G., Nasisse M.P., Larsen H.S., et al. Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis. Invest Ophthalmol Vis Sci 1984, 25:938-944.
122. Sarangi P.P., Kim B., Kurt-Jones E.A., et al. Innate recognition network driving herpes simplex virus-induced corneal immunopathology: role of the toll pathway in early inflammatory events in stromal keratitis. JVirol 2007, 81:11128-11138.
123. Sarangi PP, Rouse BT: Herpetic keratitis, in Levin L, Albert DM (eds): Ocular Disease. Mechanisms and Management, Saunders; Philadelphia 2010, pp. 92-97.
124. Scanlan P.M., Tiwari V., Bommireddy S., Shukla D. Spinoculation of heparan sulfate deficient cells enhances HSV-1 entry, but does not abolish the need for essential glycoproteins in viral fusion. JVirol Methods 2005, 128:104-112.
125. Sharma S., Mulik S., Kumar N., et al. An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus1-induced immunopathology. JVirol 2011, 85:5995-6007.
126. Shen F.H., Wang S.W., Yeh T.M., et al. Absence of CXCL10 aggravates herpes stromal keratitis with reduced primary neutrophil influx in mice. JVirol 2013, 87:8502-8510.
127. Shimeld C., Hill T., Blyth B., et al. An improved model of recurrent herpetic eye disease in mice. Curr Eye Res 1989, 8:1193-1205.
128. Shirane J., Nakayama T., Nagakubo D., et al. Corneal epithelial cells and stromal keratocytes efficently produce CC chemokine-ligand 20 (CCL20) and attract cells expressing its receptor CCR6 in mouse herpetic stromal keratitis. Curr Eye Res 2004, 28:297-306.
129. Shukla D., Liu J., Blaiklock P., et al. Anovel role for 3-O-sulfated heparan sulfate in Herpes simplex virus 1 entry. Cell 1999, 99:13-22.
130. Smith J.S., Robinson N.J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. JInfect Dis 2002, 186:S3-28.
131. Spear P.G., Longnecker R. Herpesvirus entry: an update. JVirol 2003, 77:10179-10185.
132. Streilein J.W. Ocular immune privelege: the eye takes a dim but practical view of immunity and inflammation. JLeukoc Biol 2003, 74:179-185.
133. Streilein J.W., Okamoto S., Sano Y., Taylor A.W. Neural control of ocular immune privilege. Ann NY Acad Sci 2000, 917:297-306.
134. Stuart P.M., Keadle T.L. Recurrent herpetic stromal keratitis in mice: a model for studying human HSK. Clin Dev Immunol 2012, 2012:728480.
135. Su Y.H., Yan X.T., Oakes J.E., et al. Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection. JVirol 1996, 70:1277-1281.
136. Suryawanshi A., Mulik S., Sharma S., et al. Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor. JImmunol 2011, 186:3653-3665.
137. Suryawanshi A., Veiga-Parga T., Reddy P.B., et al. IL-17A differentially regulates corneal vascular endothelial growth factor (VEGF)-A and soluble VEGF receptor 1 expression and promotes corneal angiogenesis after herpes simplex virus infection. JImmunol 2012, 188:3434-3446.
138. Tamesis R.R., Messmer E.M., Rice B.A., et al. The role of natural killer cells in the development of herpes simplex virus type 1 induced stromal keratitis in mice. Eye 1994, 8:298-306.
139. Thomas J., Gangappa S., Kanangat S., et al. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. JImmunol 1997, 158:1383-1391.
140. Thomas J., Kanangat S., Rouse B.T. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. JInterferon Cytokine Res 1998, 18:681-690.
141. Thomas J., Rouse B.T. Immunopathogenesis of herpetic ocular disease. Immunol Res 1997, 16:375-386.
142. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011, 56:95-113.
143. Tshionyi M., Shay E., Lunde E., et al. Hemangiogenesis and lymphangiogenesis in corneal pathology. Cornea 2012, 31:74-80.
144. Tumpey T.M., Chen S.H., Oakes J.E., et al. Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea. JVirol 1996, 70:898-904.
145. Tumpey T.M., Cheng H., Yan X.T., et al. Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. JLeukoc Biol 1998, 63:486-492.
146. Vassileva P.I., Hergeldzhieva T.G. Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol 2009, 247:1701-1706.
147. von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003, 3:867-878.
148. Watari K., Nakao S., Fotovati A., et al. Role of macrophages in inflammatory lymphangiogenesis: enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation. Biochem Biophys Res Commun 2008, 377:826-831.
149. West D.M., Del Rosso C.R., Yin X.T., et al. CXCL1 but not IL-6 is required for recurrent herpetic stromal keratitis. JImmunol 2014, 192:1762-1767.
150. Wickham S., Carr D.J. Molecular mimicry versus bystander activation: herpetic stromal keratitis. Autoimmunity 2004, 37:393-397.
151. Wilhelmus K.R. Diagnosis and management of herpes simplex stromal keratitis. Cornea 1987, 6:286-291.
152. Wu F.T., Stefanini M.O., Mac Gabhann F., et al. Asystems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. JCell Mol Med 2010, 14:528-552.
153. Wuest T., Zheng M., Efstathiou S., et al. The herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization. PLoS Pathog 2011, 7:e1002278.
154. Wuest T.R., Carr D.J. VEGF-A expression by HSV-1 infected cells drives corneal lymphangiogenesis. JExp Med 2010, 207:101-115.
155. Yan X.T., Tumpey T.M., Kunkel S.L., et al. Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea. Invest Ophthalmol Vis Sci 1998, 39:1854-1862.
156. Zhang S.Y., Jouanguy E., Ugolini S., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317:1522-1527.